Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith R. Leonard sold 3,486 shares of KYTHERA Biopharmaceuticals stock on the open market in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $32.54, for a total transaction of $113,434.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.57% during mid-day trading on Tuesday, hitting $32.00. 159,051 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a 1-year low of $21.21 and a 1-year high of $56.36. The stock’s 50-day moving average is $33.69 and its 200-day moving average is $40.06. The company’s market cap is $725.0 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($3.18) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.67) by $2.51. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-3.33 earnings per share for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.